PAHO says Pfizer's vaccine approval raises hope of deployment soon

Latest News

PAHO says Pfizer's vaccine approval raises hope of deployment soon

Thursday, December 03, 2020

Print this page Email A Friend!

KINGSTON, Jamaica — Assistant Director of the Pan American Health Organization (PAHO), Dr Jarbas Barbosa, says he United Kingdom's approval of Pfizer Incorporated's coronavirus (COVID-19) vaccine has further raised the hope of one becoming available for deployment to countries soon.

Pfizer, along with Moderna and AstraZeneca, are the three manufacturers whose candidate vaccines had reached advanced stage-three clinical trials, which precedes regulatory authorities' approval and World Health Organization (WHO) prequalification and authorisation.

“We understand that [over] the next [several] days or weeks, other vaccines will be authorised. I think that there is a very positive expectation that it might be possible to have a vaccine soon, to be used in countries,” Dr Barbosa said.

He was speaking during PAHO's COVID-19 digital briefing yesterday.

Dr Barbosa advised that vaccine prequalification by the WHO is closely linked with and based on work and evaluations undertaken by countries' regulatory authorities, as also the entity's independently sourced information.

Consequent on this, he said there is no vaccine that has already been recommended and authorised and available for use.

Dr Barbosa said based on developments regarding Pfizer's vaccine, among others, “I am certain that in the coming weeks, we will have [additional] vaccines”.

He disclosed that the WHO was also negotiating for the authorisation of vaccines for emergency use, adding that this has been discussed within the context of the COVID-19 Vaccine Global Access (COVAX) Facility.

The facility is designed to accelerate equitable access by countries globally to appropriate, safe and efficacious vaccines.

Noting that several regulatory authorities have adopted special procedures in order to facilitate a faster approval process for emergency use, Dr Barbosa explained that regulatory authorities review the data from phases one and two of clinical trials once they have been completed.

He added that phase-three trial data are, thereafter, reviewed by the regulatory authorities, upon completion of the phase and added to information already analysed.

“This will also allow [for the maintenance of] everything that is needed to guarantee a fast and thorough analysis, based on sound criteria to analyse all of the necessary data,” the Assistant Director further outlined.

Dr Barbosa indicated that in using COVAX, “we can [and will] have a better idea about the number of vaccines available for administration”.

Noting that vaccines are initially produced on a limited basis, he said this is largely the reason behind the recommendation that the most vulnerable persons in beneficiary countries be among the first to be inoculated.

“That is to say, vaccinate, first, health workers as well as the elderly and persons with chronic diseases. This will certainly be the first phase of the vaccination campaign. We are going to [focus on] how to use that vaccine to control [COVID-19] transmission,” Dr Barbosa added.

Over the past week, the region of the Americas recorded 1.6 million new COVID-19 cases and 22,000 deaths.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon